Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284695 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL3721728 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL19709158 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL19709160 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL19549038 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL20828930 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL13837117 | 0.93 | TYMP (0.52) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL20603110 | 0.93 | TYMP (0.52) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL21905171 | 0.93 | TYMP (0.52) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL10592428 | 0.93 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4293035-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022172994-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | 味の素株式会社 | 2022-08-18 | — | — | WO | disclosed |
| US-6884881-B1 | 2′-Substituted RNA preparation | AVECIA LIMITED (GB) | 2005-04-26 | — | — | US | disclosed |
| EP-1165584-B1 | 2'-SUBSTITUTED RNA PREPARATION | AVECIA LTD (GB) | 2004-01-21 | — | — | EP | disclosed |
| US-6090932-A | Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement | PROLIGO LLC (US) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, NOX4, POLRMT | TYMP 101/4885P2RY14 2303/4885P2RY2 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.